SynthesisAging2021
Association between
Synthesis in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Evaluation ofFrontiers in medicine · 2026Pooled it
- Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Evaluation of +49 A>G (rs231775) Variant in CTLA4 Gene and SCTLA-4 Serum Levels in Plaque Psoriasis in a Mestizo Mexican Population.International journal of molecular sciences · 2026Article
- The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Targeting GM-CSF in Rheumatoid Arthritis: Advances in Cytokine-Directed Immunotherapy and Clinical Implications.Life (Basel, Switzerland) · 2025Review
- The genetic puzzle of rheumatoid arthritis: Causes, progression, and treatment.Biochemistry and biophysics reports · 2025Review
- Efficacy of CLT4A variants as immunoregulatory molecules among Vitiligo patients in Saudi Arabia.Scientific reports · 2025Article
- T Cell Dysregulation in Rheumatoid Arthritis: from Genetic Susceptibility to Established Disease.Current rheumatology reports · 2025Review
- Decoding the genetic influence of CT60 non-coding polymorphism in CTLA-4 gene and sCTLA-4 biomarker with rheumatoid arthritis in the Indian population.Molecular biology reports · 2024Article
- Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP).Blood research · 2024Article
- Epidemiology and Risk Factors for Rheumatoid Arthritis Development.Mediterranean journal of rheumatology · 2023Review
- An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis.Journal of personalized medicine · 2023Review
- Immune checkpoints in rheumatoid arthritis: progress and promise.Frontiers in immunology · 2023Review
- Current understanding of CTLA-4: from mechanism to autoimmune diseases.Frontiers in immunology · 2023Review
- Cloning and identification of the CTLA-4IgV gene and functional application of vaccine in Xinjiang sheep.Open life sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic T lymphocyte-associated protein 4 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.